Characterization of the Burkholderia cenocepacia TonB mutant as a potential live attenuated vaccine

Gonzalo A. Pradenas, Julia N. Myers, Alfredo G. Torres

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


Burkholderia cenocepacia is an opportunistic pathogen prevalent in cystic fibrosis patients, which is particularly difficult to treat, causing chronic and eventually fatal infections. The lack of effective treatment options makes evident the need to develop alternative therapeutic or prophylactic approaches. Vaccines, and live attenuated vaccines, are an unexplored avenue to treat B. cenocepacia infections. Here we constructed and characterized a B. cenocepacia tonB mutant strain, which was unable to actively transport iron, to test whether this single gene deletion mutant (strain renamed GAP001) protected against an acute respiratory B. cenocepacia lethal infection. Here we show that the mutant strain GAP001 is attenuated, and effective at protecting against B. cenocepacia challenge. Intranasal administration of GAP001 to BALB/c mice resulted in almost complete survival with high degree of bacterial clearance.

Original languageEnglish (US)
Article number33
Issue number4
StatePublished - Dec 2017


  • Attenuated strain
  • Burkholderia cenocepacia
  • TonB
  • Vaccine

ASJC Scopus subject areas

  • Immunology
  • Pharmacology
  • Drug Discovery
  • Infectious Diseases
  • Pharmacology (medical)


Dive into the research topics of 'Characterization of the Burkholderia cenocepacia TonB mutant as a potential live attenuated vaccine'. Together they form a unique fingerprint.

Cite this